Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study-Reference-Cited by-同舟云学术

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

Published:2014-02 Issue:2 Volume:46 Page:182-186
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Cascinu Stefano,Berardi Rossana,Sobrero Alberto,Bidoli Paolo,Labianca Roberto,Siena Salvatore,Ferrari Daris,Barni Sandro,Aitini Enrico,Zagonel Vittorina,Caprioni Francesco,Villa Federica,Mosconi Stefania,Faloppi Luca,Tonini Giuseppe,Boni Corrado,Conte Pierfranco,Di Costanzo Francesco,Cinquini Michela

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;Journal of Clinical Oncology,1997

2. Pancreatic cancer;Hidalgo;New England Journal of Medicine,2010

3. Pancreatic cancer: molecular pathogenesis and new therapeutic targets;Wong;Nature Reviews Gastroenterology & Hepatology,2009

4. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with a advanced pancreatic cancer: a randomised, multicentre, phase II study;Cascinu;Lancet Oncology,2008

5. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Sowthwest Oncology Group-directed Intergroup Trial S0205;Philip;Journal of Clinical Oncology,2010

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CPEB1 Controls NRF2 Proteostasis and Ferroptosis Susceptibility in Pancreatic Cancer;International Journal of Biological Sciences;2024

2. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review);Oncology Reports;2023-10-04

3. Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials;Genes & Diseases;2023-01

4. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma;Current Molecular Pharmacology;2022-12

5. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma;The Oncologist;2022-11-25